Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
Top Cited Papers
- 1 May 2007
- journal article
- Published by Elsevier in The Lancet
- Vol. 369 (9574) , 1693-1702
- https://doi.org/10.1016/s0140-6736(07)60777-6
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Effect of Human Papillomavirus Vaccines on Vulvar, Vaginal, and Anal Intraepithelial Lesions and Vulvar CancerObstetrics & Gynecology, 2006
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006
- Trends in the Incidence of Invasive and In Situ Vulvar CarcinomaObstetrics & Gynecology, 2006
- Preliminary results of 5% immiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3American Journal of Obstetrics and Gynecology, 2006
- Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO2 laser vaporization, photodynamic therapy, excision and vulvectomyGynecologic Oncology, 2006
- Vulvar Intraepithelial NeoplasiaObstetrics & Gynecology, 2005
- Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patientsGynecologic Oncology, 2005
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Exact power and sample size for vaccine efficacy studiesCommunications in Statistics - Theory and Methods, 1998
- Natural history of vaginal intraepithelial neoplasiaCancer, 1991